What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?
7 equities research analysts have issued 1 year price objectives for Synergy Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $11.50 in the next twelve months.
When will Synergy Pharmaceuticals announce their earnings?
Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Synergy Pharmaceuticals stock?
Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
- BTIG Research analysts commented, "In sum, we think SGYP's Trulance (plecanatide) which was recently granted FDA approval for the treatment of chronic constipation may have a lower incidence of diarrhea side effect (~5% with plecanatide vs. placebo at ~1%) which could interest physicians and patients."He adds, "Ultimately, we believe Trulance will become a meaningful new product in the GI treatment category with sales potential approaching $500M by 2020. With ~40M Americans suffering from chronic constipation and there being widespread usage of OTC laxatives (which does not adequately treat chronic symptoms in many cases), we believe the opportunity for SGYP's Trulance is significant. While we do think Trulance will ultimately take share from Linzess, we think the real market opportunity will be in expanding the overall Rx treatment market. Ultimately, we think the launch of Trulance will lead to more patients switching from OTC laxatives to Rx treatments." (1/26/2017)
According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (1/26/2017)
- Rodman & Renshaw analysts commented, "Synergy's flagship product, which we anticipate to be launched later this quarter under the trade name Trulance', was approved for the treatment of chronic idiopathic constipation (CIC) over a week ahead of the original PDUFA date of January 29, 2017. Investors should note that, in addition to the near-term launch of Trulance', Synergy also anticipates filing the supplemental New Drug Application (NDA) for the drug in treatment of constipation-predominant irritable bowel syndrome (IBS-C) later this quarter. Trulance' could win approval in the IBS-C indication by the end of this year, in our view, given a roughly 10-month review period. We note that the drug demonstrated solid efficacy and safety across four robustly-designed Phase 3 trials in CIC and IBS-C. In the wake of the landmark milestone of the Trulance' approval, we reiterate our Buy rating and raise our 12-month price target to $18.00 per share from $17.00 on SGYP." (1/20/2017)
Who owns Synergy Pharmaceuticals stock?
Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Paulson & CO. Inc. (13.39%), Orbimed Advisors LLC (10.14%), State Street Corp (3.49%), Armistice Capital LLC (0.94%), Kingdon Capital Management L.L.C. (0.87%) and Perceptive Advisors LLC (0.27%). Company insiders that own Synergy Pharmaceuticals stock include Alan Joslyn, Bernard Denoyer, John P Brancaccio and Paulson & Co Inc.
Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?
Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates, Allianz Asset Management AG, Kingdon Capital Management L.L.C., GRT Capital Partners L.L.C., Thompson Siegel & Walmsley LLC, Metropolitan Life Insurance Co. NY and Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Synergy Pharmaceuticals stock in the last year include John P Brancaccio and Paulson & Co Inc.
Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?
Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Orbimed Advisors LLC, State Street Corp, Perceptive Advisors LLC, Armistice Capital LLC, Russell Investments Group Ltd., Pacad Investment Ltd. and Oberweis Asset Management Inc..
How do I buy Synergy Pharmaceuticals stock?
Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Synergy Pharmaceuticals stock cost?
One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $5.48.